Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Beate Timmermann, Mark C. Gebhardt et al.|European Journal of Cancer|2019Cited by 724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa Marina, Lisa A. Teot, Sigbjørn Smeland et al.|The Lancet Oncology|2016Cited by 537
Aneurysmal Bone Cyst: A Review of 150 PatientsHenry J. Mankin, Mark C. Gebhardt|Journal of Clinical Oncology|2005Cited by 459
USP6 and CDH11 Oncogenes Identify the Neoplastic Cell in Primary Aneurysmal Bone Cysts and Are Absent in So-Called Secondary Aneurysmal Bone CystsAndré M. Oliveira, Jonathan A. Fletcher, Antonio R. Pérez‐Atayde et al.|American Journal Of Pathology|2004Cited by 432
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan Bielack, Mark L. Bernstein, Sigbjørn Smeland et al.|Journal of Clinical Oncology|2015Cited by 419